Veru Stock News

Nuveen Asset Management LLC boosted its position in Veru Inc. (NASDAQ:VERU) by 111.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 721,915 shares of the companys stock after acquiring an additional 380,746 shares during the quarter. Nuveen Asset Management LLCs []

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, to

Brokerages predict that Veru Inc. (NASDAQ:VERU) will post $18.26 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Verus earnings. The lowest sales estimate is $17.00 million and the highest is $19.00 million. Veru reported sales of $11.75 million in the same quarter last year, which indicates a positive []

-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3 rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed, val

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared firs

MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, t

MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, t

An analyst raised his price target for the stock.

An analyst argues that the company has far more value than many realize.

Veru, Inc. (VERU) CEO Mitchell Steiner on Q3 2021 Results - Earnings Call Transcript

Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2 prescription net revenues climbed 150%

Veru Inc. (VERU) delivered earnings and revenue surprises of 50.00% and 26.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

--Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs—

MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, t

--Sabizabulin is a novel oral androgen receptor transport disruptor-- -- In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resis